z-logo
open-access-imgOpen Access
Autogenous Bone and Bioactive Glass around Implants Placed Simultaneously with Ridge Splitting for the Treatment of Horizontal Bony Defects: A Randomised Clinical Trial
Author(s) -
Walid Elamrousy,
Mohamed O. T. Badr,
Dalia Rasheed Issa
Publication year - 2021
Publication title -
international journal of dentistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.61
H-Index - 33
eISSN - 1687-8736
pISSN - 1687-8728
DOI - 10.1155/2021/2457328
Subject(s) - dentistry , ridge , medicine , bioactive glass , bone resorption , implant , resorption , bone formation , orthodontics , surgery , geology , paleontology , pathology , endocrinology
Objective To compare using autogenous bone with or without bioactive glass in ridge splitting of horizontal bone defects combined with simultaneous implant placement.Materials and Methods In control group, bone expansion was performed and autogenous bone was used to augment the intercortical bone defect. In study group, autogenous bone was mixed with bioactive glass (1 : 1 in volume). In both groups, the implants were inserted simultaneously with ridge splitting. Six months following implant insertion, bone width and height were evaluated. Statistical analysis utilizing paired Student's t -test was used for comparing results within the same group, whereas independent samples t -test was used for intergroup variables comparison.Results The mean bone width and labial and mesiodistal crestal bone height values were increased significantly in both groups from baseline to 6 months postoperatively. Comparing the two groups showed nonstatistical significant difference regarding the labial crestal bone loss, while the ridge width gain values were significantly higher in the study group than in the control group. The mesiodistal bone loss was significantly higher in control group than in study group.Conclusion Autogenous bone was mixed with bioactive glass (1 : 1 in volume) to fill intercortical defect created after ridge splitting to decrease peri-implant bone resorption associated with autogenous bone alone. This trial is registered with clinical trial registration: NCT04814160 .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom